All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| AXSM / Axsome Therapeutics, Inc.
|
|
|
|
|
|
|
|
| CLTEF / Clara Technologies Corp.
|
|
|
|
|
|
|
|
| DSGN / Design Therapeutics, Inc.
|
|
|
|
|
|
|
|
| IKNA / Ikena Oncology, Inc.
|
|
|
|
|
|
|
|
| US9266131005 / Viela Bio, Inc.
|
|
|
|
|
|
|
|
| KURA / Kura Oncology, Inc.
|
|
|
|
|
|
|
|
| CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| IVA / Inventiva S.A. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| ISEE / IVERIC bio Inc
|
|
|
|
|
|
|
|
| EWTX / Edgewise Therapeutics, Inc.
|
|
|
|
|
|
|
|
| GOSS / Gossamer Bio, Inc.
|
|
|
|
|
|
|
|
| KDMN / Kadmon Holdings Inc
|
|
|
|
|
|
|
|
| FGEN / FibroGen, Inc.
|
|
|
|
|
|
|
|
| KNSA / Kiniksa Pharmaceuticals, Ltd.
|
|
|
|
|
|
|
|
| ARQT / Arcutis Biotherapeutics, Inc.
|
|
|
|
|
|
|
|
| XLRN / Acceleron Pharma Inc
|
|
|
|
|
|
|
|
| CCXI / ChemoCentryx Inc
|
|
|
|
|
|
|
|
| ACRS / Aclaris Therapeutics, Inc.
|
|
|
|
|
|
|
|
| NGM / NGM Biopharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| KRON / Kronos Bio, Inc.
|
|
|
|
|
|
|
|
| JYAC / Jiya Acquisition Corp - Class A
|
|
|
|
|
|
|
|
| FHTX / Foghorn Therapeutics Inc.
|
|
|
|
|
|
|
|
| CRIS / Curis, Inc.
|
|
|
|
|
|
|
|
| CRDF / Cardiff Oncology, Inc.
|
|
|
|
|
|
|
|
| HLXA / Helix Acquisition Corp - Class A
|
|
|
|
|
|
|
|
| IMAB / I-Mab - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| RNA / Avidity Biosciences, Inc.
|
|
|
|
|
|
|
|
| FDMT / 4D Molecular Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RXDX / Prometheus Biosciences Inc
|
|
|
|
|
|
|
|
| RVMD / Revolution Medicines, Inc.
|
|
|
|
|
|
|
|
| CLDX / Celldex Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ARVN / Arvinas, Inc.
|
|
|
|
|
|
|
|
| PMVP / PMV Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| MRUS / Merus N.V.
|
|
|
|
|
|
|
|
| RCUS / Arcus Biosciences, Inc.
|
|
|
|
|
|
|
|
| TSHA / Taysha Gene Therapies, Inc.
|
|
|
|
|
|
|
|
| DYN / Dyne Therapeutics, Inc.
|
|
|
|
|
|
|
|
| APLS / Apellis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
